Prudential Financial Inc. trimmed its position in MedReleaf Corp. (NYSE:LEA) by 52.0% in the third quarter, according to its most recent filing with the SEC. The fund owned 265,174 shares of the company’s stock after selling 287,493 shares during the period. Prudential Financial Inc. owned 0.39% of MedReleaf Corp. worth $45,897,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Benjamin F. Edwards & Company Inc. lifted its stake in shares of MedReleaf Corp. by 6.1% in the 2nd quarter. Benjamin F. Edwards & Company Inc. now owns 831 shares of the company’s stock valued at $118,000 after acquiring an additional 48 shares during the last quarter. Toronto Dominion Bank lifted its stake in shares of MedReleaf Corp. by 10.9% in the 2nd quarter. Toronto Dominion Bank now owns 852 shares of the company’s stock valued at $121,000 after acquiring an additional 84 shares during the last quarter. Mountain Capital Investment Advisors Inc bought a new position in shares of MedReleaf Corp. in the 2nd quarter valued at $126,000. Global X Management Co. LLC lifted its stake in shares of MedReleaf Corp. by 16.5% in the 2nd quarter. Global X Management Co. LLC now owns 1,023 shares of the company’s stock valued at $145,000 after acquiring an additional 145 shares during the last quarter. Finally, Parallel Advisors LLC lifted its stake in shares of MedReleaf Corp. by 3.9% in the 2nd quarter. Parallel Advisors LLC now owns 1,117 shares of the company’s stock valued at $166,000 after acquiring an additional 42 shares during the last quarter.

In other news, SVP Mel Stephens sold 2,411 shares of MedReleaf Corp. stock in a transaction dated Monday, September 25th. The stock was sold at an average price of C$172.88, for a total value of C$416,813.68. Following the completion of the transaction, the senior vice president now directly owns 44,484 shares of the company’s stock, valued at approximately C$7,690,393.92. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Jonathan F. Foster sold 2,854 shares of MedReleaf Corp. stock in a transaction dated Tuesday, September 26th. The stock was sold at an average price of C$173.39, for a total value of C$494,855.06. Following the completion of the transaction, the director now directly owns 7,761 shares of the company’s stock, valued at C$1,345,679.79. The disclosure for this sale can be found here. Over the last three months, insiders sold 9,404 shares of company stock valued at $1,601,681.

MedReleaf Corp. (LEA) opened at C$175.43 on Friday. MedReleaf Corp. has a 12-month low of C$117.53 and a 12-month high of C$178.80.

MedReleaf Corp. (NYSE:LEA) last posted its quarterly earnings data on Wednesday, October 25th. The company reported C$3.96 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of C$3.80 by C$0.16. MedReleaf Corp. had a return on equity of 31.60% and a net margin of 6.17%. The firm had revenue of C$4.98 billion during the quarter, compared to analyst estimates of C$4.84 billion. During the same period last year, the company posted $3.19 EPS. The business’s quarterly revenue was up 10.1% on a year-over-year basis.

TRADEMARK VIOLATION WARNING: “Prudential Financial Inc. Reduces Stake in MedReleaf Corp. (LEA)” was originally posted by Daily Political and is the sole property of of Daily Political. If you are accessing this report on another domain, it was illegally stolen and reposted in violation of US & international trademark & copyright law. The correct version of this report can be accessed at https://www.dailypolitical.com/2017/11/12/prudential-financial-inc-reduces-stake-in-medreleaf-corp-lea.html.

Several research analysts recently issued reports on the company. Guggenheim lowered MedReleaf Corp. from a “buy” rating to a “neutral” rating and set a $167.00 target price for the company. in a research report on Thursday, October 26th. Barclays PLC set a $171.00 target price on MedReleaf Corp. and gave the stock a “hold” rating in a research report on Friday, October 20th. UBS AG lowered MedReleaf Corp. from a “buy” rating to a “neutral” rating and raised their target price for the stock from $158.00 to $182.00 in a research report on Tuesday, October 3rd. Jefferies Group LLC assumed coverage on MedReleaf Corp. in a research report on Thursday, September 28th. They set a “buy” rating and a $197.00 target price for the company. Finally, Robert W. Baird reaffirmed a “buy” rating and set a $178.00 target price on shares of MedReleaf Corp. in a research report on Friday, September 1st. Two equities research analysts have rated the stock with a sell rating, seven have given a hold rating and nine have issued a buy rating to the company. MedReleaf Corp. has an average rating of “Hold” and a consensus price target of C$173.13.

MedReleaf Corp. Company Profile

Lear Corporation (Lear) is a supplier to the global automotive industry. The Company is engaged in supplying seating, electrical distribution systems and electronic modules, as well as related sub-systems, components and software, to automotive manufacturers. The Company’s segments include Seating and E-Systems.

Institutional Ownership by Quarter for MedReleaf Corp. (NYSE:LEA)

Receive News & Ratings for MedReleaf Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MedReleaf Corp. and related companies with MarketBeat.com's FREE daily email newsletter.